The 3rd ALS Drug Development Summit 2024 is dedicated to innovating a new era of earlier diagnosis & prognosis to advance stratification of heterogeneous ALS populations.
The 3rd ALS Drug Development Summit 2024 covers topics such as:
- Assessing Neurofilament Light Changes in Presymptomatic Sporadic ALS
- Promising Longer-Term Biomarker Data from NurOwn Program in ALS: Spotlight on NfL in EAP Extension Cohort
- Developing Robust In Vitro Assays to Mimic Complex ALS Pathologies
- Innovating More Objective Biomarkers to Transform Clinical Assessments of ALS Severity
- Navigating the Complexity of Causative Genes & Risk Factors for ALS to Give Rise to Next-Generation Targets
- Modernizing the Clinical Trial Approach as More Treatments Emerge & Endpoints Evolve
- Revitalizing ALS Drug Development to More Effectively Meet the Requirements of People Living with ALS
- Navigating Commercial Bottlenecks to Determine Access to Treatment for People Living with ALS
- Revitalizing In Vivo Models for Replicating Motor Neuronal Pathologies
- Reviewing the Latest Preclinical Progress of Novel ALS Targets
- Keeping Pace with the Evolving Approval Landscape for ALS Therapeutics
- Exploring Emerging Clinical ALS Pipeline Innovation
- Future Directions & Research Priorities: What Will the ALS Landscape Look Like in Years to Come?
The 3rd ALS Drug Development Summit 2024 brings together:
- Head of Neuroscience Experimental Medicine, Takeda Pharmaceutical Co. Ltd.
- Co-CEO, BrainStorm Cell Therapeutics
- Head of Target Validation, AcuraStem Inc.
- Senior Scientist, Sanofi
- VP and Global Head Medical Affairs, Amylyx Pharmaceuticals
- Director - Computational Biology, Prevail Therapeutics
- Principle Scientist II, Novartis AG
- Associate Director, Regeneron Pharmaceuticals Inc
- Vice President & Head of Clinical Development, QurAlis Corp.
- Vice President of Research and Development, NeuroSense Therapeutics
- Advocate, I AM ALS
- Nurse Practitioner & Healey & AMG Center for ALS Research Site Director, Massachusetts General Hospital (MGH) and Harvard Medical School
- Chie
